South Africa Ph II trial enrolls for TB vaccine

A potential tuberculosis vaccine developed by the Netherlands-based drugmaker Crucell and the USA/South African non-profit Aeras Global TB Vaccine Foundation has begun enrolling volunteers on a Phase II clinical trial. Scientists from the University of Cape Town's Lung Institute and the South African Tuberculosis Vaccine Institute expect to begin inoculations shortly. A Phase I study of the Aeras-402/Crucell Ad35 candidate vaccine was successfully completed earlier this year (Marketletter April 14).